Gene expression of 61 FFPE tissues of DLBCL patients at high-risk (aaIPI 2 or 3)

ABSTRACT: Current staging classifications do not accurately predict the benefit of high-dose chemotherapy (HDC) with autologous stem-cell transplantation (ASCT) for patients with diffuse large B-cell lymphoma (DLBCL) at high risk (age-adjusted International Index [aaIPI] score 2 or 3), who have achieved first complete remission after R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) treatment. We aim to construct a genetic prognostic model for improving individualized risk stratification and response prediction for HDC/ASCT therapy. We identified differentially expressed mRNAs associated with relapse of DLBCL.

ORGANISM(S): Homo sapiens

PROVIDER: GSE156309 | GEO | 2023/08/16

REPOSITORIES: GEO